Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 18 04:00PM ET
5.36
Dollar change
-0.14
Percentage change
-2.55
%
IndexRUT P/E- EPS (ttm)-2.70 Insider Own30.63% Shs Outstand31.13M Perf Week-1.65%
Market Cap166.89M Forward P/E- EPS next Y-2.82 Insider Trans0.00% Shs Float21.60M Perf Month-1.11%
Income-76.98M PEG- EPS next Q-0.66 Inst Own66.63% Short Float3.47% Perf Quarter-23.65%
Sales0.00M P/S- EPS this Y8.19% Inst Trans3.13% Short Ratio14.15 Perf Half Y-39.84%
Book/sh6.32 P/B0.85 EPS next Y-12.00% ROA-42.09% Short Interest0.75M Perf Year5.72%
Cash/sh6.02 P/C0.89 EPS next 5Y-1.04% ROE-45.95% 52W Range4.69 - 11.90 Perf YTD-10.96%
Dividend Est.- P/FCF- EPS past 5Y- ROI-38.51% 52W High-54.96% Beta0.73
Dividend TTM- Quick Ratio12.75 Sales past 5Y0.00% Gross Margin- 52W Low14.29% ATR (14)0.40
Dividend Ex-Date- Current Ratio12.75 EPS Y/Y TTM-17.54% Oper. Margin- RSI (14)47.76 Volatility4.50% 7.20%
Employees58 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.57
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q10.11% Payout- Rel Volume0.29 Prev Close5.50
Sales Surprise- EPS Surprise-2.01% Sales Q/Q- EarningsNov 13 BMO Avg Volume52.91K Price5.36
SMA20-0.87% SMA50-4.62% SMA200-23.55% Trades Volume15,296 Change-2.55%
Date Action Analyst Rating Change Price Target Change
Jan-31-25Initiated KeyBanc Capital Markets Overweight
Sep-16-24Upgrade Ladenburg Thalmann Neutral → Buy $16
Apr-29-24Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-24Initiated JMP Securities Mkt Outperform $14
Dec-15-23Resumed Jefferies Buy $17 → $12
Oct-05-23Initiated Maxim Group Buy
Jun-02-23Initiated Oppenheimer Outperform $25
May-08-23Initiated BMO Capital Markets Outperform $25
Apr-27-23Initiated Ladenburg Thalmann Buy $22
Apr-20-23Initiated H.C. Wainwright Buy $24
Feb-06-25 08:16AM
04:54AM
Feb-05-25 03:45PM
08:00AM
Nov-13-24 07:00AM
08:00AM Loading…
Oct-17-24 08:00AM
Oct-16-24 04:00PM
Oct-12-24 08:28AM
Oct-11-24 08:00AM
Sep-14-24 03:10AM
Sep-10-24 08:00AM
Sep-09-24 07:00AM
Aug-15-24 09:40AM
Aug-13-24 08:00AM
Jun-21-24 09:40AM
09:40AM Loading…
Jun-05-24 09:40AM
May-29-24 08:00AM
May-28-24 09:47AM
May-20-24 09:40AM
May-14-24 01:54PM
08:00AM
May-10-24 08:50AM
Apr-29-24 07:08AM
Apr-24-24 04:01PM
Apr-16-24 08:01PM
Apr-10-24 08:00AM
Apr-09-24 10:32AM
07:00AM
Mar-30-24 05:31AM
Mar-28-24 12:52PM
08:00AM Loading…
08:00AM
Mar-05-24 04:30PM
Mar-04-24 08:00AM
Feb-27-24 08:00AM
Feb-08-24 08:00AM
Feb-06-24 08:00AM
Jan-12-24 04:00PM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
Nov-28-23 08:00AM
Nov-21-23 08:00AM
08:00AM
Nov-09-23 08:01AM
Oct-16-23 08:00AM
Sep-28-23 04:05PM
Sep-19-23 04:32PM
Sep-05-23 04:05PM
Aug-30-23 08:00AM
Aug-17-23 04:00PM
Aug-11-23 07:00AM
Aug-08-23 12:38PM
Jul-20-23 08:00AM
Jun-29-23 04:49PM
Jun-22-23 04:00PM
Jun-02-23 08:00AM
May-09-23 10:43AM
08:00AM
08:00AM
May-07-23 08:17AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-18-23 08:00AM
Mar-28-23 08:00AM
Mar-06-23 08:00AM
Feb-27-23 08:00AM
Feb-15-23 05:40AM
Feb-14-23 10:15AM
Jan-22-23 03:31PM
Nov-14-22 10:16PM
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Devroe EricChief Operating OfficerMay 17 '24Option Exercise1.0410,00010,40069,097May 21 04:04 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM